Log in

NASDAQ:HOOKHookipa Pharma Stock Price, Forecast & News

+0.07 (+0.65 %)
(As of 08/7/2020 04:00 PM ET)
Today's Range
Now: $10.76
50-Day Range
MA: $10.89
52-Week Range
Now: $10.76
Volume24,989 shs
Average Volume55,961 shs
Market Capitalization$234.89 million
P/E RatioN/A
Dividend YieldN/A
HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.22 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:HOOK



Sales & Book Value

Annual Sales$11.94 million
Book Value$5.46 per share


Net Income$-43,040,000.00
Net Margins-333.02%


Market Cap$234.89 million
Next Earnings Date8/13/2020 (Confirmed)
OptionableNot Optionable
+0.07 (+0.65 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HOOK News and Ratings via Email

Sign-up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Hookipa Pharma (NASDAQ:HOOK) Frequently Asked Questions

How has Hookipa Pharma's stock been impacted by COVID-19 (Coronavirus)?

Hookipa Pharma's stock was trading at $9.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, HOOK shares have increased by 16.3% and is now trading at $10.76.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of Hookipa Pharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hookipa Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Hookipa Pharma

When is Hookipa Pharma's next earnings date?

Hookipa Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020.
View our earnings forecast for Hookipa Pharma

How were Hookipa Pharma's earnings last quarter?

Hookipa Pharma Inc (NASDAQ:HOOK) announced its earnings results on Thursday, May, 14th. The company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by $0.01. The firm earned $3.70 million during the quarter, compared to analyst estimates of $4.36 million. Hookipa Pharma had a negative net margin of 333.02% and a negative return on equity of 36.53%.
View Hookipa Pharma's earnings history

What price target have analysts set for HOOK?

2 Wall Street analysts have issued twelve-month price targets for Hookipa Pharma's shares. Their forecasts range from $15.00 to $23.00. On average, they expect Hookipa Pharma's stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 76.6% from the stock's current price.
View analysts' price targets for Hookipa Pharma

Has Hookipa Pharma been receiving favorable news coverage?

Media coverage about HOOK stock has trended extremely negative this week, InfoTrie reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Hookipa Pharma earned a daily sentiment score of -4.8 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
View the latest news about Hookipa Pharma

Who are some of Hookipa Pharma's key competitors?

What other stocks do shareholders of Hookipa Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hookipa Pharma investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Atreca (BCEL), Homology Medicines (FIXX), Kaleido Biosciences (KLDO), LogicBio Therapeutics (LOGC), Stoke Therapeutics (STOK), Akero Therapeutics (AKRO) and Tcr2 Therapeutics (TCRR).

Who are Hookipa Pharma's key executives?

Hookipa Pharma's management team includes the following people:
  • Mr. Joern Aldag, Pres, CEO & Director (Age 60)
  • Mr. Daniel Pinschewer, Founder & Chief Scientific Officer (Age 44)
  • Dr. Reinhard Kandera, CFO & Director (Age 50)
  • Mr. Anders Lilja Ph.D., Sr. VP of Technical Devel. (Age 46)
  • Mrs. Nina Waibel, Communications & Investor Relations Mang.

When did Hookipa Pharma IPO?

(HOOK) raised $100 million in an IPO on Thursday, April 18th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Kempen was co-manager.

What is Hookipa Pharma's stock symbol?

Hookipa Pharma trades on the NASDAQ under the ticker symbol "HOOK."

Who are Hookipa Pharma's major shareholders?

Hookipa Pharma's stock is owned by many different institutional and retail investors. Top institutional investors include New York State Common Retirement Fund (0.06%), First Trust Advisors LP (0.06%) and UBS Group AG (0.02%). Company insiders that own Hookipa Pharma stock include Anders Lilja, Bros Advisors Lp Baker, Igor Matushansky, Klaus Orlinger and Sofinnova Capital Vi Fcpr.
View institutional ownership trends for Hookipa Pharma

Which major investors are selling Hookipa Pharma stock?

HOOK stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG. Company insiders that have sold Hookipa Pharma company stock in the last year include Anders Lilja, Igor Matushansky, Klaus Orlinger, and Sofinnova Capital Vi Fcpr.
View insider buying and selling activity for Hookipa Pharma

Which major investors are buying Hookipa Pharma stock?

HOOK stock was acquired by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, and First Trust Advisors LP. Company insiders that have bought Hookipa Pharma stock in the last two years include Bros Advisors Lp Baker, and Sofinnova Capital Vi Fcpr.
View insider buying and selling activity for Hookipa Pharma

How do I buy shares of Hookipa Pharma?

Shares of HOOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Hookipa Pharma's stock price today?

One share of HOOK stock can currently be purchased for approximately $10.76.

How big of a company is Hookipa Pharma?

Hookipa Pharma has a market capitalization of $234.89 million and generates $11.94 million in revenue each year. The company earns $-43,040,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Hookipa Pharma employs 56 workers across the globe.

What is Hookipa Pharma's official website?

The official website for Hookipa Pharma is www.hookipapharma.com.

How can I contact Hookipa Pharma?

Hookipa Pharma's mailing address is 350 FIFTH AVENUE 72ND FLOOR SUITE 7240, NEW YORK NY, 10118. The company can be reached via phone at 431-890-6360 or via email at [email protected]

This page was last updated on 8/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.